71 | HS&M JUNE/JULY 2017
ing up to commercialization. Indeed,
some venture firms such as venBio have
started shifting their funding model, and
an increasing number of them are also
funding Phase III through to commercialization.
For investors, given the success of the
first-time launches, it seems that engaging early and becoming the funder
of choice for emerging companies will
be even more rewarding in the future.
Should this become commonplace,
emerging companies would be able to
retain their autonomy and culture of innovation.
In sum, the analysis of companies that
launched a product for the first time
between 2006 and 2015 revealed that
companies can rely on several different
funding models and employ a variety
of strategies. There are successful examples of each approach, but there are
many considerations that should go
into the decision, including a company’s
short- and long-term goals, the degree of
control it wants to retain, and its ability
to rely on outsourcing partners, to name
a few. Large pharmaceutical companies
and venture capitalists should recognize
the options—and success—that emerging
companies are having and revisit their
own business strategies accordingly. •
1 There were 22 more launches in 2016, which can be seen
2All trademarks, trade names and product names contained
herein are the property of their respective owners. The use
or display of other parties’ trademarks, trade names and
product names is not intended to imply, and should not be
construed to imply, a relationship with, or endorsement or
sponsorship of QuintilesIMS Incorporated or its subsidiaries
by such other party.
3“Biopharmaceutical Research & Development: The Process
Behind New Medicines,” PhRMA, August 20, 2015.
4 This analysis covers only those companies (whether Going
it Alone or in Partnerships) that actually launched products.
Companies whose launches failed were not analyzed.
Ester Oben Etah
Principal, Launch Excellence,
Ester has over 20 years
of experience working in
the pharmaceutical and
biotechnology space both in
the US and Internationally.
With her medical and scientific background, she
brings a lot of therapeutic area expertise as well as
an in-depth understanding of the rapidly changing
dynamics of the industry. While at QuintilesIMS,
Ester developed experience in market assessment
& forecasting and patient level data analysis. In
addition, Ester has experience in product portfolio
valuation & decision analysis, product licensing &
deal valuation, mergers & acquisition analysis and
life cycle management.
Principal, Launch Excellence,
Bill is an expert in the field
of pharmaceutical launch
excellence with over 20 years
of experience. He leads the
Launch Center of Excellence
for the US at QuintilesIMS
where he focuses on launch
readiness, tracking and performance diagnostics
utilizing patient data, statistical modeling,
qualitative and quantitative research.
Bill leads a team of professionals responsible
for developing thought leadership to provide
innovative approaches for launching a brand.
The research focuses on patient acquisition and
prescriber adoption and productivity. The group
has examined how launch success varies by
market need and product differentiation creating
launch archetypes. Findings have fueled offerings
that focus on launch strategy, commercialization
tactics and performance monitoring.